Abstract 1172
Background
Rhabdomyosarcoma (RMS) represents a malignant tumor of skeletal muscle origin, accounting for 5-10% of childhood cancers and more than 50% of pediatric soft tissue sarcoma. The head and neck occupied about 35% of the main sites of RMSs and most of these tumors are located in orbit, which contributes to 10% of all sites of RMSs. Due to the rarity of orbital RMS, the published studies of the clinical and pathological factors of orbital RMS could only provide limited information due to the small numbers of cohort or single institution. The aim of the current study was to evaluate the cumulative incidence of cancer-specific and competing risk death for patients with orbital RMS after surgery and build nomograms to predict survival based on a large population-based cohort.
Methods
Patients pathologically diagnosed with orbital RMS between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively collected. Nomograms for estimating overall survival (OS) and cancer-specific survival (CSS) were established based on Cox regression model and Fine and Grey’s model. The precision of the nomograms was evaluated and compared using concordance index (C-index) and the area under receiver operating characteristic (ROC) curve (AUC).
Results
A total of identified 217 patients with orbital RMS were retrospectively collected. The 10-, 20- and 40-year OS rates and cancer-specific mortality were 82.5%, 72.2% and 48.9%, respectively and 14.8%, 21.7% and 21.7%, respectively. The established nomograms were well calibrated and validated, with C-index of 0.901 and 0.944 for OS prediction, 0.923 and 0.904, for CSS prediction in the training and validation cohort, respectively. The values of AUC for 10-, 20-, and 40-year OS and CSS prediction were 0.908, 0.826 and 0.847, and 0.924, 0.863 and 0.863, respectively.
Conclusions
The survival rates were evaluated for patients with orbital RMS and the specialized nomograms were established for OS and CSS prediction for the first time, which showed relatively good performances and could be convenient individualized predictive tools for prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by the funding of Sun Yat-sen University Grant for Medical Humanities Practice and Teaching (No. 23000-18008023).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract